Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

This trial is testing AMB-05X — a personalized cancer vaccine — in colorectal cancer patients who have completed curative surgery and treatment but still show a positive ctDNA test. A ctDNA (circulating tumor DNA) test detects tiny fragments of cancer DNA in the blood, even when scans show no visible disease. A positive result after treatment suggests a high risk of the cancer coming back, and this vaccine aims to prevent that recurrence. **You may be eligible if...** - You have been diagnosed with adenocarcinoma of the colon or rectum (stage I–IV) - You have completed all curative-intent treatments and have no visible disease on scans - At least 28 days after finishing all treatments, a ctDNA test (Signatera) came back positive - You are in reasonably good health **You may NOT be eligible if...** - You have visible, measurable cancer remaining after treatment - You have not completed all planned standard treatments - You have significant immune system problems or other serious health conditions Talk to your doctor to see if this trial is right for you.